Niagen Bioscience (NAGE) Cash from Operations (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Cash from Operations of 1194000.0 for Q1 2026, down 115.15% year-over-year from 7883000.0 in Q1 2025, and down 269.6% quarter-over-quarter from 704000.0 in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) Cash from Operations (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Cash from Operations for 14 consecutive years, with 1194000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 115.15% year-over-year to 1194000.0; the TTM figure through Mar 2026 stood at 4427000.0 (down 77.52% YoY), while the FY2025 annual figure was 13504000.0, up 11.52% from the prior year.
- Cash from Operations fell to 1194000.0 in Q1 2026 per NAGE's latest filing, from 704000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 8583000.0 in Q4 2024 and bottomed at 7198000.0 in Q1 2022.
- Historically, Cash from Operations has averaged 966941.18 across 5 years, with a median of 649000.0 in 2023.
- Annual changes were most pronounced in 2025 — Cash from Operations surged 2572.2% — and 2026, when it slumped 115.15%.
- Niagen Bioscience's Cash from Operations stood at 328000.0 in 2022, then jumped by 297.87% to 649000.0 in 2023, then jumped by 1222.5% to 8583000.0 in 2024, then sank by 91.8% to 704000.0 in 2025, then sank by 269.6% to 1194000.0 in 2026.
- Business Quant data shows NAGE's Cash from Operations at 1194000.0 in Q1 2026, 704000.0 in Q4 2025, and 3700000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | 2.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.77 Mn |
| Mar 31, 2026 | -1.19 Mn |
| Dec 31, 2025 | 679,000.00 |
| Sep 30, 2025 | 3.69 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 7.88 Mn |
| Dec 31, 2024 | 8.58 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | -264,000.00 |
| Mar 31, 2024 | 295,000.00 |
| Dec 31, 2023 | 649,000.00 |
| Sep 30, 2023 | 396,000.00 |
| Jun 30, 2023 | 3.28 Mn |
| Mar 31, 2023 | 2.79 Mn |
| Dec 31, 2022 | -328,000.00 |
| Sep 30, 2022 | -3.74 Mn |
| Jun 30, 2022 | -3.83 Mn |
| Mar 31, 2022 | -7.20 Mn |
| Dec 31, 2021 | -4.94 Mn |
| Sep 30, 2021 | -5.92 Mn |